CINCINNATI, Feb. 11 Kendle (Nasdaq: KNDL) announced today that it will release its fourth quarter and full-year 2009 financial results after the market closes on Wednesday, Feb. 24, 2010. The Company will host a telephone conference call and simultaneous webcast on Thursday, Feb. 25 at 8:00 a.m. Eastern Time. A question and answer session will follow.
Conference Call Instructions
To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 946-0709. Participants outside North America should dial (719) 457-2632. All participants should enter conference ID number 5419062. A replay will be available through 5 p.m. Eastern Time on March 25, 2010, by dialing (888) 203-1112 in North America or 719-457-0820 outside of North America and entering conference ID number 5419062.
To access the live webcast, visit the Company Web site at www.kendle.com or link to the Webcast directly at http://www.videonewswire.com/event.asp?id=65769. Instructions for accessing the webcast are provided at both sites. The webcast will be archived at www.kendle.com (click on "For Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on March 25, 2010. Please note that webcast participants will not be able to ask questions.
System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.
Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's Web site at www.kendle.com.
SOURCE Kendle International Inc.